A 47-year-old man with newly diagnosed pulmonary tuberculosis is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. He has a history of major depressive disorder and is currently stable on sertraline 100 mg daily. After 4 weeks of TB treatment, he reports worsening mood, poor sleep, and feelings of hopelessness. What is the most likely explanation for his deteriorating mental health?
Q42
A 6-month-old infant is brought to the emergency department with a 4-hour history of high fever (39.5°C), irritability, and a rapidly spreading purpuric rash. The child appears shocked with capillary refill time of 5 seconds, heart rate 180/min, and blood pressure 65/40 mmHg. Blood cultures are obtained. What is the most appropriate immediate antibiotic therapy?
Q43
A 41-year-old man from Moldova presents with an 8-week history of productive cough, fever, and weight loss. Chest X-ray shows bilateral upper lobe cavitation. Three sputum samples are smear-positive for acid-fast bacilli. Molecular testing (Xpert MTB/RIF) detects Mycobacterium tuberculosis with rifampicin resistance. What is the most appropriate next investigation to guide treatment?
Q44
A 38-year-old woman with systemic lupus erythematosus on hydroxychloroquine and prednisolone 15 mg daily presents with a 7-week history of headache, personality change, and intermittent low-grade fever. MRI brain shows basal meningeal enhancement. CSF analysis shows: opening pressure 28 cmH2O, protein 2.1 g/L, glucose 1.8 mmol/L (plasma glucose 5.2 mmol/L), white cells 180/mm³ (85% lymphocytes). India ink stain is positive. What is the most appropriate initial antifungal treatment regimen?
Q45
A 2-year-old child is brought to the emergency department with a 6-hour history of fever (39.2°C), drowsiness, and refusing to feed. On examination, she has a bulging fontanelle and a purpuric rash on her trunk and limbs. Blood cultures are taken and intravenous ceftriaxone is commenced immediately. Which statutory notification requirement applies in this case?
Q46
A 55-year-old man with newly diagnosed smear-positive pulmonary tuberculosis is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. After 3 weeks of treatment, he develops painful swelling of his right great toe with erythema and tenderness. His serum uric acid level is elevated at 520 µmol/L. What is the most appropriate initial management step?
Q47
A 44-year-old woman is diagnosed with smear-positive pulmonary tuberculosis. Molecular testing (GeneXpert MTB/RIF) confirms Mycobacterium tuberculosis with rifampicin resistance detected. She is referred to the regional MDR-TB service. Further drug susceptibility testing shows: resistant to rifampicin and isoniazid, sensitive to pyrazinamide, ethambutol, fluoroquinolones, and aminoglycosides. What minimum number of effective drugs and treatment duration are recommended for her MDR-TB regimen according to current WHO guidelines?
Q48
A 53-year-old man completes 9 months of treatment for drug-sensitive pulmonary tuberculosis (rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by rifampicin and isoniazid for 7 months). His treatment was extended from 6 to 9 months because of cavitating disease on initial chest X-ray and positive sputum culture at 2 months. He is now asymptomatic. End-of-treatment chest X-ray shows residual fibrotic changes in the right upper lobe but no active disease. His most recent sputum samples (taken at 8 months) were smear and culture negative. What follow-up is most appropriate?
Q49
A 31-year-old man presents to the emergency department with a 10-hour history of severe headache, fever, neck stiffness, and photophobia. He appears acutely unwell. Blood pressure is 98/55 mmHg, heart rate 118 bpm, temperature 39.3°C, GCS 14/15. There is no rash. CT head is performed and shows no contraindication to lumbar puncture. Blood cultures are taken. What is the most appropriate next step in management?
Q50
A 5-year-old girl presents with a 3-day history of fever, headache, and increasing drowsiness. On examination, temperature is 39.2°C, GCS 12/15 (E3 V4 M5), there is neck stiffness and a positive Kernig's sign. Lumbar puncture is performed: opening pressure 24 cm H₂O, white cells 850/mm³ (85% lymphocytes), protein 3.2 g/L, glucose 1.1 mmol/L (plasma glucose 5.6 mmol/L). Gram stain is negative. Ziehl-Neelsen stain is negative. She was born in the UK and has received all routine vaccinations including BCG at birth (her mother is from India). What is the most appropriate initial treatment regimen?
Serious & Notifiable Infections UK Medical PG Practice Questions and MCQs
Question 41: A 47-year-old man with newly diagnosed pulmonary tuberculosis is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. He has a history of major depressive disorder and is currently stable on sertraline 100 mg daily. After 4 weeks of TB treatment, he reports worsening mood, poor sleep, and feelings of hopelessness. What is the most likely explanation for his deteriorating mental health?
A. Drug-induced hepatitis causing hepatic encephalopathy
B. Direct neurotoxic effect of isoniazid causing depression
C. Rifampicin-induced metabolism of sertraline reducing its effectiveness (Correct Answer)
D. Pyrazinamide-related hyperuricaemia affecting mood
E. Psychological reaction to the diagnosis of tuberculosis
Explanation: ***Rifampicin-induced metabolism of sertraline reducing its effectiveness***
- **Rifampicin** is a potent inducer of **cytochrome P450 enzymes**, particularly CYP3A4, which is responsible for the metabolism of **sertraline**.
- This induction leads to significantly **reduced plasma concentrations** of sertraline, diminishing its therapeutic effect and causing a relapse of the patient's **depressive symptoms**.
*Drug-induced hepatitis causing hepatic encephalopathy*
- While rifampicin and isoniazid can cause **hepatitis**, hepatic encephalopathy typically presents with altered consciousness, confusion, and **asterixis**, not primarily a worsening of mood.
- This condition is usually associated with significant liver dysfunction and would likely manifest with other signs of liver failure such as **jaundice** or severe derangements in liver function tests.
*Direct neurotoxic effect of isoniazid causing depression*
- **Isoniazid (INH)** neurotoxicity commonly presents as **peripheral neuropathy** due to pyridoxine (vitamin B6) deficiency, or, less frequently, **seizures** or **psychosis**.
- Although psychiatric side effects are possible, INH is not a primary or common cause of isolated worsening of a previously stable major depressive disorder.
*Pyrazinamide-related hyperuricaemia affecting mood*
- **Pyrazinamide** is known to cause **hyperuricaemia** by inhibiting renal uric acid excretion, which can lead to **gout**.
- There is no established clinical link or evidence suggesting that **elevated uric acid levels** directly cause an acute worsening of depressive symptoms.
*Psychological reaction to the diagnosis of tuberculosis*
- While a chronic illness diagnosis can certainly impact mental health, the patient was described as **stable on sertraline** prior to treatment, and symptoms began after starting the **enzyme-inducing** TB regimen.
- The timing and nature of the mood deterioration strongly point to a **pharmacokinetic drug interaction** rather than a purely psychological reaction.
Question 42: A 6-month-old infant is brought to the emergency department with a 4-hour history of high fever (39.5°C), irritability, and a rapidly spreading purpuric rash. The child appears shocked with capillary refill time of 5 seconds, heart rate 180/min, and blood pressure 65/40 mmHg. Blood cultures are obtained. What is the most appropriate immediate antibiotic therapy?
A. Intravenous ceftriaxone 80 mg/kg as a single dose
B. Intravenous cefotaxime 50 mg/kg plus amoxicillin 50 mg/kg (Correct Answer)
C. Intramuscular benzylpenicillin 300 mg as a single dose
D. Intravenous vancomycin 15 mg/kg plus gentamicin 2.5 mg/kg
E. Intravenous meropenem 40 mg/kg as a single dose
Explanation: ***Intravenous cefotaxime 50 mg/kg plus amoxicillin 50 mg/kg***
- The clinical presentation of **high fever, irritability, rapidly spreading purpuric rash, and shock** is highly suggestive of **meningococcal septicaemia**, a life-threatening emergency requiring immediate broad-spectrum antibiotic coverage.
- In infants up to 3-6 months, empirical therapy must include coverage for **Listeria monocytogenes** (with **amoxicillin** or ampicillin), as **third-generation cephalosporins** like cefotaxime lack activity against it, alongside coverage for *Neisseria meningitidis* and *Streptococcus pneumoniae*.
*Intravenous ceftriaxone 80 mg/kg as a single dose*
- While **ceftriaxone** is an excellent third-generation cephalosporin for suspected **meningococcal disease** and **pneumococcal infections**, it **lacks activity against *Listeria monocytogenes***, which is a crucial pathogen to cover in young infants with severe sepsis/meningitis.
- Ceftriaxone is generally avoided in neonates due to risks of **biliary sludging** and displacement of bilirubin, though this risk lessens by 6 months, the lack of Listeria coverage remains a significant drawback.
*Intramuscular benzylpenicillin 300 mg as a single dose*
- **Intramuscular benzylpenicillin** is a critical **pre-hospital intervention** for suspected **meningococcal disease** when intravenous access is not immediately available or hospital transfer is delayed.
- In an emergency department setting with a critically ill, shocked infant and established IV access, comprehensive **intravenous broad-spectrum therapy** is required, making single-dose IM penicillin insufficient.
*Intravenous vancomycin 15 mg/kg plus gentamicin 2.5 mg/kg*
- This combination is typically reserved for suspected **MRSA infections**, **healthcare-associated sepsis**, or in specific circumstances where highly resistant Gram-positive pathogens are a concern.
- While **gentamicin** provides Gram-negative coverage, this regimen is not the first-line empirical choice for community-acquired bacterial meningitis/sepsis in infants, which is primarily driven by *N. meningitidis*, *S. pneumoniae*, and *L. monocytogenes*.
*Intravenous meropenem 40 mg/kg as a single dose*
- **Meropenem** is a **carbapenem**, a very broad-spectrum antibiotic reserved for severe **multi-drug resistant infections** or in cases where first-line cephalosporins have failed or resistance is proven.
- It is not recommended as the initial **empirical therapy** for a previously healthy infant presenting with a typical community-acquired purpuric rash and shock, as simpler, more targeted regimens are preferred initially.
Question 43: A 41-year-old man from Moldova presents with an 8-week history of productive cough, fever, and weight loss. Chest X-ray shows bilateral upper lobe cavitation. Three sputum samples are smear-positive for acid-fast bacilli. Molecular testing (Xpert MTB/RIF) detects Mycobacterium tuberculosis with rifampicin resistance. What is the most appropriate next investigation to guide treatment?
A. Repeat Xpert MTB/RIF testing on a new sputum sample
B. Send sputum for full drug susceptibility testing including first and second-line drugs (Correct Answer)
C. Start standard four-drug therapy pending culture results
D. CT chest to assess extent of disease
E. HIV testing and CD4 count
Explanation: ***Send sputum for full drug susceptibility testing including first and second-line drugs***
- Rifampicin resistance detected by **Xpert MTB/RIF** is highly predictive of **multidrug-resistant tuberculosis (MDR-TB)**, as rifampicin resistance is strongly associated with isoniazid resistance.
- Comprehensive **drug susceptibility testing (DST)** for first and second-line drugs is essential to design an effective treatment regimen that prevents further resistance and optimizes clinical outcomes.
*Repeat Xpert MTB/RIF testing on a new sputum sample*
- The **Xpert MTB/RIF** assay is highly specific for detecting rifampicin resistance; repeating it would delay the necessary comprehensive resistance profiling.
- In patients from high-risk areas like **Moldova**, a positive result is considered reliable and should prompt immediate escalation to definitive **culture-based DST**.
*Start standard four-drug therapy pending culture results*
- Standard therapy (RIPE) is inappropriate because the organism is already known to be **rifampicin-resistant**, meaning the core of the regimen is ineffective.
- Starting standard therapy in the presence of known resistance risks the development of further **amplified resistance** to the remaining active drugs like ethambutol or pyrazinamide.
*CT chest to assess extent of disease*
- While a **CT chest** may show the anatomical extent of disease or complications like cavitation, it provides no information about the drug sensitivity of the pathogen.
- Management of tuberculosis is primarily driven by the **microbiological phenotype** and drug resistance patterns rather than radiographic severity.
*HIV testing and CD4 count*
- Although **HIV screening** is recommended for all TB patients, it is not the priority investigation for guiding the specific **anti-tuberculosis drug regimen**.
- Identifying the full profile of drug resistance is the immediate clinical requirement to prevent treatment failure and community transmission of **MDR-TB**.
Question 44: A 38-year-old woman with systemic lupus erythematosus on hydroxychloroquine and prednisolone 15 mg daily presents with a 7-week history of headache, personality change, and intermittent low-grade fever. MRI brain shows basal meningeal enhancement. CSF analysis shows: opening pressure 28 cmH2O, protein 2.1 g/L, glucose 1.8 mmol/L (plasma glucose 5.2 mmol/L), white cells 180/mm³ (85% lymphocytes). India ink stain is positive. What is the most appropriate initial antifungal treatment regimen?
A. Amphotericin B liposomal and flucytosine for 2 weeks, then fluconazole (Correct Answer)
B. Fluconazole monotherapy at high dose (800 mg daily)
C. Voriconazole monotherapy for 6 weeks
D. Amphotericin B liposomal monotherapy for 4 weeks
E. Itraconazole and flucytosine combination therapy
Explanation: ***Amphotericin B liposomal and flucytosine for 2 weeks, then fluconazole***
- The patient's presentation with headache, personality change, basal meningeal enhancement, classic CSF findings (high protein, low glucose, lymphocytic pleocytosis), and a **positive India ink stain** confirms **Cryptococcal meningitis**.
- The recommended initial treatment (induction phase) for severe cryptococcal meningitis, especially in immunocompromised patients, is a combination of **liposomal amphotericin B** and **flucytosine** for 2 weeks, followed by fluconazole for consolidation.
*Fluconazole monotherapy at high dose (800 mg daily)*
- **Fluconazole monotherapy** is less effective for the induction phase of cryptococcal meningitis and is associated with slower CSF sterilization and higher mortality compared to combination therapy.
- It is typically used for the **consolidation phase** after initial induction or for milder cases without CNS involvement.
*Voriconazole monotherapy for 6 weeks*
- **Voriconazole** is primarily effective against *Aspergillus* and some *Candida* species, and is not a first-line antifungal agent for the treatment of **Cryptococcus neoformans** infections.
- There is insufficient evidence to support its use as an initial induction therapy for cryptococcal meningitis over standard regimens.
*Amphotericin B liposomal monotherapy for 4 weeks*
- While **Amphotericin B** is a crucial component, monotherapy is inferior to its combination with **flucytosine**, which provides synergistic fungicidal activity and faster clearance of the organism from the CSF.
- The addition of flucytosine allows for a shorter induction period (2 weeks) and reduces the overall exposure to amphotericin B, mitigating potential **nephrotoxicity**.
*Itraconazole and flucytosine combination therapy*
- **Itraconazole** exhibits poor penetration into the central nervous system (**CNS**), making it an unsuitable agent for treating cryptococcal meningitis.
- While flucytosine is appropriate, itraconazole's poor CNS pharmacokinetics mean this combination would be ineffective for a meningeal infection.
Question 45: A 2-year-old child is brought to the emergency department with a 6-hour history of fever (39.2°C), drowsiness, and refusing to feed. On examination, she has a bulging fontanelle and a purpuric rash on her trunk and limbs. Blood cultures are taken and intravenous ceftriaxone is commenced immediately. Which statutory notification requirement applies in this case?
A. Notification must be made within 24 hours to the local Health Protection Team
B. Notification must be made immediately by telephone to the local Health Protection Team (Correct Answer)
C. Notification is only required after microbiological confirmation
D. Notification is only required for fatal cases
E. Notification is the responsibility of the microbiologist once cultures are positive
Explanation: ***Notification must be made immediately by telephone to the local Health Protection Team*** - The clinical presentation (fever, drowsiness, bulging fontanelle, purpuric rash) is highly suggestive of **meningococcal disease**, a **medical emergency** and a **notifiable disease**. - For such serious infections, **immediate telephone notification** to the **Health Protection Team** is crucial for prompt public health action, including rapid contact tracing and prophylaxis. *Notification must be made within 24 hours to the local Health Protection Team* - While many notifiable diseases have a 24-hour reporting window, **meningococcal disease** requires **immediate notification** due to its rapid progression and high infectivity. - The urgency is to allow for **rapid contact tracing** and **chemoprophylaxis** to prevent secondary cases and further transmission. *Notification is only required after microbiological confirmation* - **Statutory notification** for highly contagious and severe diseases like **meningococcal meningitis** is based on **clinical suspicion** to avoid delays in public health intervention. - Waiting for **laboratory confirmation** would significantly delay essential actions like **contact management** and risk further spread of the disease. *Notification is only required for fatal cases* - All suspected cases of **notifiable diseases**, irrespective of outcome, must be reported to enable comprehensive **disease surveillance** and **outbreak control**. - Reporting non-fatal cases is crucial for understanding disease epidemiology and **preventing further cases** in the community. *Notification is the responsibility of the microbiologist once cultures are positive* - The **attending medical practitioner** who first suspects a notifiable disease has the **primary legal responsibility** to notify. - While laboratories also notify upon positive results, the initial clinical suspicion and **immediate notification** by the clinician are paramount for timely public health action before lab results are available.
Question 46: A 55-year-old man with newly diagnosed smear-positive pulmonary tuberculosis is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. After 3 weeks of treatment, he develops painful swelling of his right great toe with erythema and tenderness. His serum uric acid level is elevated at 520 µmol/L. What is the most appropriate initial management step?
A. Discontinue pyrazinamide and substitute with levofloxacin
B. Continue all four drugs and start allopurinol
C. Continue all four drugs and start colchicine for symptom control (Correct Answer)
D. Reduce the dose of pyrazinamide by 50%
E. Continue all four drugs and start high-dose prednisolone
Explanation: ***Continue all four drugs and start colchicine for symptom control***
- **Pyrazinamide** is known to cause **hyperuricemia** and can precipitate acute **gouty arthritis** by inhibiting renal uric acid excretion.
- It is critical to continue the full anti-tuberculosis regimen during the intensive phase to ensure efficacy, while managing the acute gout attack symptomatically with agents like **colchicine** or NSAIDs.
*Discontinue pyrazinamide and substitute with levofloxacin*
- **Pyrazinamide** is a cornerstone drug in the initial phase of TB treatment, crucial for sterilizing lesions and shortening treatment duration; it should only be discontinued if side effects are severe and uncontrollable.
- Substituting with **levofloxacin** is generally reserved for cases of drug resistance or severe intolerance to first-line agents, which is not indicated here.
*Continue all four drugs and start allopurinol*
- **Allopurinol** is a urate-lowering therapy used for chronic management of hyperuricemia and prevention of future gout attacks, but it should not be initiated during an **acute gout attack** as it can prolong or worsen symptoms.
- For pyrazinamide-induced hyperuricemia, symptomatic treatment of gout flares is usually sufficient without the need for chronic urate-lowering therapy unless flares are frequent and severe.
*Reduce the dose of pyrazinamide by 50%*
- Reducing the dose of **pyrazinamide** without proper clinical justification can lead to **sub-therapeutic drug levels**, increasing the risk of **treatment failure** and the development of drug resistance.
- Maintaining appropriate drug concentrations is essential for effective **tuberculosis eradication**, especially during the intensive phase.
*Continue all four drugs and start high-dose prednisolone*
- While corticosteroids can be effective for acute gout, **high-dose prednisolone** is not typically the first-line choice when other options like **colchicine** or NSAIDs are available and appropriate.
- High-dose corticosteroids carry the risk of **immunosuppression**, which needs careful consideration in a patient with active **pulmonary tuberculosis**.
Question 47: A 44-year-old woman is diagnosed with smear-positive pulmonary tuberculosis. Molecular testing (GeneXpert MTB/RIF) confirms Mycobacterium tuberculosis with rifampicin resistance detected. She is referred to the regional MDR-TB service. Further drug susceptibility testing shows: resistant to rifampicin and isoniazid, sensitive to pyrazinamide, ethambutol, fluoroquinolones, and aminoglycosides. What minimum number of effective drugs and treatment duration are recommended for her MDR-TB regimen according to current WHO guidelines?
A. At least 3 effective drugs for a total of 9 months
B. At least 4 effective drugs for a total of 9-12 months (Correct Answer)
C. At least 4 effective drugs for a total of 18-20 months
D. At least 5 effective drugs for a total of 18-24 months
E. At least 5 effective drugs for a total of 12-15 months
Explanation: ***At least 4 effective drugs for a total of 9-12 months*** - According to **WHO guidelines**, patients with **MDR-TB** (resistant to isoniazid and rifampicin) who have preserved **fluoroquinolone sensitivity** are candidates for the **all-oral shorter regimen**. - This regimen requires a minimum of **4 effective drugs** in the initial phase and typically lasts **9 to 12 months** total, improving patient compliance compared to longer traditional protocols. *At least 3 effective drugs for a total of 9 months* - A minimum of **3 drugs** is generally insufficient to maintain the necessary bactericidal and sterilizing power required for **drug-resistant tuberculosis**. - Standard shortest regimens (like BPaL) use 3 drugs but are reserved for specific populations; however, the broader **WHO shorter regimen** standard for eligible MDR-TB patients is at least **4 drugs**. *At least 4 effective drugs for a total of 18-20 months* - An 18–20 month duration refers to the **longer individualized regimen**, which is no longer the primary choice for patients eligible for shorter courses. - This longer duration is reserved for cases involving **fluoroquinolone resistance**, treatment failure, or extensive **extrapulmonary disease**, none of which are indicated here. *At least 5 effective drugs for a total of 18-24 months* - Using **5 effective drugs** for up to 24 months was the traditional approach for complicated or **Pre-XDR/XDR-TB** before the advent of newer oral agents. - Current guidelines prioritize **shorter durations** to reduce toxicity and improve **treatment completion rates** when susceptibility allows. *At least 5 effective drugs for a total of 12-15 months* - This specific drug count and duration combination does not align with the standardized **WHO-recommended** categories for MDR-TB management. - While individualized regimens vary, the target for shorter regimens is **9-12 months**, and the target for longer regimens is over **18 months**, making this option inconsistent with current guidelines.
Question 48: A 53-year-old man completes 9 months of treatment for drug-sensitive pulmonary tuberculosis (rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by rifampicin and isoniazid for 7 months). His treatment was extended from 6 to 9 months because of cavitating disease on initial chest X-ray and positive sputum culture at 2 months. He is now asymptomatic. End-of-treatment chest X-ray shows residual fibrotic changes in the right upper lobe but no active disease. His most recent sputum samples (taken at 8 months) were smear and culture negative. What follow-up is most appropriate?
A. Routine clinic review at 3, 6, and 12 months with repeat chest X-rays and sputum samples
B. Discharge with written advice to seek medical attention if symptoms recur (Correct Answer)
C. Continue rifampicin and isoniazid for a further 3 months then review
D. Monthly clinic reviews for 6 months with clinical assessment only
E. Arrange CT thorax in 3 months to assess for occult disease
Explanation: ***Discharge with written advice to seek medical attention if symptoms recur***
- Patients who have completed a full course of treatment for **drug-sensitive TB** with clinical and **microbiological cure** (negative cultures) do not require routine long-term follow-up.
- **NICE guidelines** recommend discharging patients with clear information about symptoms of **relapse** and how to re-access services if needed.
*Routine clinic review at 3, 6, and 12 months with repeat chest X-rays and sputum samples*
- Routine **radiological surveillance** and sputum testing are not cost-effective and have not been shown to improve outcomes in successfully treated patients.
- This approach is typically reserved for complex cases such as **Multi-Drug Resistant (MDR) TB**, not drug-sensitive disease.
*Continue rifampicin and isoniazid for a further 3 months then review*
- The patient has already completed an extended **9-month regimen** necessitated by the initial **cavitation** and delayed culture conversion; further extension is unnecessary.
- Prolonging treatment beyond evidenced standards increases the risk of **drug toxicity** without providing additional benefit against relapse.
*Monthly clinic reviews for 6 months with clinical assessment only*
- Routine clinical assessment is not required if the patient is **asymptomatic** and has confirmed **negative sputum cultures** at the end of treatment.
- Resources are better prioritized toward ensuring **treatment adherence** in active cases rather than monitoring those already cured.
*Arrange CT thorax in 3 months to assess for occult disease*
- **CT imaging** is not indicated for monitoring post-treatment when the patient is asymptomatic and the **end-of-treatment X-ray** shows only expected fibrotic changes.
- **Residual fibrosis** is a common sequela of healed pulmonary TB and does not represent active or occult infection.
Question 49: A 31-year-old man presents to the emergency department with a 10-hour history of severe headache, fever, neck stiffness, and photophobia. He appears acutely unwell. Blood pressure is 98/55 mmHg, heart rate 118 bpm, temperature 39.3°C, GCS 14/15. There is no rash. CT head is performed and shows no contraindication to lumbar puncture. Blood cultures are taken. What is the most appropriate next step in management?
A. Proceed immediately to lumbar puncture before administering antibiotics
B. Administer intravenous ceftriaxone then perform lumbar puncture within 1 hour
C. Administer intravenous ceftriaxone and dexamethasone then perform lumbar puncture within 1 hour (Correct Answer)
D. Administer intravenous ceftriaxone, arrange lumbar puncture when convenient within 6 hours
E. Administer intravenous ceftriaxone, aciclovir, and dexamethasone then perform lumbar puncture
Explanation: ***Administer intravenous ceftriaxone and dexamethasone then perform lumbar puncture within 1 hour***
- In suspected **bacterial meningitis**, empirical antibiotics like **ceftriaxone** should be administered immediately to prevent rapid deterioration, especially when the patient shows signs of **sepsis** (hypotension, tachycardia).
- **Dexamethasone** should be given beforehand or with the first dose of antibiotics to reduce the risk of **neurological sequelae** and mortality, particularly in cases of pneumococcal meningitis.
*Proceed immediately to lumbar puncture before administering antibiotics*
- While obtaining a pre-antibiotic **CSF sample** is ideal for culture yield, treatment must never be delayed for a procedure in a clinically unstable or **acutely unwell** patient.
- Delayed antibiotic administration in meningitis is directly correlated with increased **morbidity and mortality**.
*Administer intravenous ceftriaxone then perform lumbar puncture within 1 hour*
- This option is incorrect because it lacks the co-administration of **dexamethasone**, which is a vital component of initial therapy in adults.
- Omitting **corticosteroids** in the initial management window can lead to increased inflammation-mediated damage during bacterial lysis.
*Administer intravenous ceftriaxone, arrange lumbar puncture when convenient within 6 hours*
- A delay of up to **6 hours** for a lumbar puncture is inappropriate; it should be performed as soon as safely possible, ideally within **1 hour** of arrival.
- Prolonged delay after antibiotics significantly reduces the diagnostic sensitivity of **CSF cultures**, although PCR may remain positive.
*Administer intravenous ceftriaxone, aciclovir, and dexamethasone then perform lumbar puncture*
- **Aciclovir** is used for **viral encephalitis**, but this patient lacks the typical features such as focal neurological deficits, seizures, or significant behavioral changes.
- The clinical presentation of sudden onset **fever, headache, and neck stiffness** points strongly toward bacterial rather than viral etiology.
Question 50: A 5-year-old girl presents with a 3-day history of fever, headache, and increasing drowsiness. On examination, temperature is 39.2°C, GCS 12/15 (E3 V4 M5), there is neck stiffness and a positive Kernig's sign. Lumbar puncture is performed: opening pressure 24 cm H₂O, white cells 850/mm³ (85% lymphocytes), protein 3.2 g/L, glucose 1.1 mmol/L (plasma glucose 5.6 mmol/L). Gram stain is negative. Ziehl-Neelsen stain is negative. She was born in the UK and has received all routine vaccinations including BCG at birth (her mother is from India). What is the most appropriate initial treatment regimen?
A. Intravenous ceftriaxone and dexamethasone
B. Rifampicin, isoniazid, pyrazinamide, ethionamide, and dexamethasone
C. Intravenous ceftriaxone, aciclovir, and dexamethasone pending further results
D. Rifampicin, isoniazid, pyrazinamide, ethambutol, and dexamethasone (Correct Answer)
E. Rifampicin, isoniazid, pyrazinamide, levofloxacin, and dexamethasone
Explanation: ***Rifampicin, isoniazid, pyrazinamide, ethambutol, and dexamethasone***
- The CSF profile showing **lymphocytic pleocytosis**, **markedly elevated protein** (3.2 g/L), and **low glucose** (CSF:plasma ratio <0.3) is highly characteristic of **tuberculous meningitis (TBM)**.
- Initial treatment for TBM requires a four-drug antitubercular regimen plus **dexamethasone**, which is shown to significantly reduce mortality and neurological morbidity.
*Intravenous ceftriaxone and dexamethasone*
- This is the standard treatment for **acute bacterial meningitis**, which typically presents with a **neutrophilic** (not lymphocytic) pleocytosis.
- While bacterial meningitis causes low glucose, the high protein and subacute presentation (GCS 12, 3-day history) point more towards the **subacute nature** of TB.
*Rifampicin, isoniazid, pyrazinamide, ethionamide, and dexamethasone*
- **Ethionamide** is sometimes used in younger children (<5 years) who cannot cooperate with visual acuity testing required for ethambutol.
- However, for a 5-year-old child, **ethambutol** remains the standard fourth agent in the preferred first-line regimen for sensitive TB.
*Intravenous ceftriaxone, aciclovir, and dexamethasone pending further results*
- This regimen covers **bacterial meningitis** and **herpes simplex encephalitis**, but viral encephalitis usually presents with **normal CSF glucose**.
- Given the epidemiological risk (maternal origin) and the classic **very low glucose and high protein**, anti-TB therapy must not be delayed.
*Rifampicin, isoniazid, pyrazinamide, levofloxacin, and dexamethasone*
- **Levofloxacin** or other fluoroquinolones are generally reserved for cases of **multidrug-resistant TB (MDR-TB)**.
- There is no clinical or epidemiological evidence in this history to suggest a drug-resistant strain as the initial suspicion.
